Navigation Links
Mylan Receives Approval for Generic Version of Precose® Tablets
Date:1/18/2011

PITTSBURGH, Jan. 18, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Acarbose Tablets, 25 mg, 50 mg and 100 mg, the generic version of Bayer's Precose® Tablets, a treatment to be used with diet and exercise to improve glycemic control in adults with type 2 diabetes.

Acarbose Tablets had U.S. sales of approximately $23 million for the 12 months ending Sept. 30, 2010, according to IMS Health. The product is available for immediate shipment.

Currently, Mylan has 169 ANDAs pending FDA approval representing $99.5 billion in annual sales, according to IMS Health. Forty-five of these pending ANDAs are potential first-to-file opportunities, representing $24 billion in annual brand sales, for the 12 months ending June 30, 2010, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 140 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information, please visit www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Announces Voluntary De-listing of 1.25% Senior Convertible Notes Due 2012 from Nasdaq
2. Mylans Dey Pharma Partners with Meda to Market EpiPen® Auto-Injector in Europe
3. Mylan Confirms First-to-File Patent Challenge Relating to Orapred ODT®
4. Mylan Receives Approval for Generic Version of Adalat® CC Tablets
5. Mylan Announces the Conversion of its Preferred Stock into Common Stock
6. Mylan Announces Final Conversion Rate for Mandatory Convertible Preferred Stock
7. Third Circuit Denies Mylan Motion for Interim Injunction
8. Mylan Reports Adjusted Diluted EPS of $0.43; Reaffirms 2010 Adjusted Diluted EPS Guidance of $1.55 - $1.65
9. Mylan Declares Quarterly Preferred Stock Dividend
10. Mylan to Appeal Court Decision in Generic Paroxetine Hydrochloride CR Case
11. Mylan Receives Approvals for Generic Versions of Hyzaar® and Cozaar®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 4, 2016  Compass Diversified Holdings (NYSE: ... owner of leading middle market businesses, announced today its ... 31, 2016. First Quarter 2016 Highlights ... ("CAD" or "Cash Flow") of $13.6 million for the ... of $15.0 million for the first quarter of 2016; ...
(Date:5/4/2016)... 2016 According to market research "Global ... Forecast to 2022 - Industry Insights by Slice Type (High, ... Others)" by P&S Market Research, the global computed tomography ... it is expected to grow at a CAGR of 5.0% ... segment is expected to witness the faster growth, CAGR of ...
(Date:5/4/2016)... DUBLIN , May 4, 2016 /PRNewswire/ ... the addition of the  "Global Multiple Myeloma ...  report to their offering.       ... Multiple Myeloma Market and Competitive Landscape Highlights ... pipeline products, Multiple Myeloma epidemiology, Multiple Myeloma ...
Breaking Medicine Technology:
(Date:5/6/2016)... , ... May 06, 2016 , ... Canadian author Mark Black is a ... Life From the Heart" around the world … with the help of his publisher Strategic ... 24, Mark Black lay in a hospital bed waiting for a miracle: He needed a ...
(Date:5/6/2016)... ... May 06, 2016 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... he has found in the Bible about helping to stop cancer. Yisrayl says there are ... his hope that the health and science industries will pay close attention and take action. ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... David Konur, CEO of Cardiovascular Institute of the South announced today that Dr. ... a live case of an Intravascular Ultrasound Guided Coronary Atherectomy. , ...
(Date:5/5/2016)... ... May 05, 2016 , ... While the practice and profession ... the impact our aging population has on communities and resources. Aging Life Care plays ... and face age-related challenges. , Aging Life Care is a holistic, client-centered approach ...
(Date:5/5/2016)... ... May 05, 2016 , ... The U.S. Food and ... e-cigarette manufacturers to submit their products through an arduous federal approval process. The ... that entered the market since February 15, 2007. That would essentially ban 99 ...
Breaking Medicine News(10 mins):